Jounce Financial Statements From 2010 to 2024
| JNCEDelisted Stock | USD 1.88 0.00 0.00% |
Check Jounce Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Jounce main balance sheet or income statement drivers, such as , as well as many exotic indicators such as . Jounce financial statements analysis is a perfect complement when working with Jounce Therapeutics Valuation or Volatility modules.
Jounce |
Jounce Therapeutics Company Return On Asset Analysis
Jounce Therapeutics' Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Jounce Therapeutics Return On Asset | -0.14 |
Most of Jounce Therapeutics' fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Jounce Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
CompetitionBased on the latest financial disclosure, Jounce Therapeutics has a Return On Asset of -0.1404. This is 98.4% lower than that of the Biotechnology sector and 99.41% lower than that of the Health Care industry. This indicator is about the same for all United States stocks average (which is currently at -0.14).
Jounce Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Jounce Therapeutics's current stock value. Our valuation model uses many indicators to compare Jounce Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Jounce Therapeutics competition to find correlations between indicators driving Jounce Therapeutics's intrinsic value. More Info.Jounce Therapeutics is rated third overall in return on equity category among related companies. It is rated fifth overall in return on asset category among related companies . Comparative valuation analysis is a catch-all model that can be used if you cannot value Jounce Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Jounce Therapeutics' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Jounce Therapeutics' earnings, one of the primary drivers of an investment's value.About Jounce Therapeutics Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Jounce Therapeutics income statement, its balance sheet, and the statement of cash flows. Jounce Therapeutics investors use historical funamental indicators, such as Jounce Therapeutics's revenue or net income, to determine how well the company is positioned to perform in the future. Although Jounce Therapeutics investors may use each financial statement separately, they are all related. The changes in Jounce Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Jounce Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Jounce Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Jounce Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts. Jounce Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 137 people.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. Note that the Jounce Therapeutics information on this page should be used as a complementary analysis to other Jounce Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Other Consideration for investing in Jounce Stock
If you are still planning to invest in Jounce Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Jounce Therapeutics' history and understand the potential risks before investing.
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities |